PA
LEGN icon

Parallel Advisors’s Legend Biotech LEGN Stock Holding History

Parallel Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.39K Sell
325
-1,759
-84% -$47.4K ﹤0.01% 2971
2026
Q1 		$37.7K Buy
2,084
+1,323
+174% +$25.2K ﹤0.01% 2155
2025
Q4 		$16.5K Sell
761
-286
-27% -$8.19K ﹤0.01% 2388
2025
Q3 		$34.1K Buy
1,047
+662
+172% +$24.4K ﹤0.01% 1987
2025
Q2 		$13.7K Buy
385
+2
+0.5% +$65 ﹤0.01% 2359
2025
Q1 		$13K Sell
383
-1,699
-82% -$60.9K ﹤0.01% 2333
2024
Q4 		$67.7K Buy
+2,082
New +$86.2K ﹤0.01% 1472

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Parallel Advisors's LEGN Position: Q2 2026 in Review

Parallel Advisors reduced its Legend Biotech (LEGN) stake by 84% in Q2 2026, selling an estimated $47.4K and leaving 325 shares worth $9.39K. The position accounts for ﹤0.01% of the portfolio, ranked #2971.

Parallel Advisors first reported a position in LEGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $67.7K in Q4 2024. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Parallel Advisors held 325 shares of Legend Biotech worth $9.39K as of Q2 2026.
  • Parallel Advisors sold 1,759 Legend Biotech shares in Q2 2026, an estimated $47.4K.
  • Legend Biotech made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #2971 holding.
  • Parallel Advisors first reported a position in Legend Biotech in Q4 2024 and has held it in 7 quarters since.
  • Parallel Advisors's Legend Biotech position peaked at $67.7K in Q4 2024.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.